Zacks Investment Research upgraded shares of Imperva Inc. (NYSE:IMPV) from a sell rating to a hold rating in a report released on Tuesday.

According to Zacks, “Imperva Inc. is engaged in the development of protection software and services for business applications and databases. The Company delivers innovative technology to give full audit accountability and separation of duties to meet regulatory compliance. It offers SecureSphere Data Security Suite to protect sensitive data from hackers and malicious insiders along with providing a fast and cost-effective route to regulatory compliance and establishes a repeatable process for data risk management. The Company’s SecureSphere offers database security solutions to secure sensitive data stored in databases, File Security solutions to protect sensitive files on file servers, storage devices, content repositories, and meet regulatory compliance mandates and Web Application Security solutions to protect web applications from cyber attacks. Imperva Inc. is headquartered in Redwood Shores, California. “

Several other analysts have also issued reports on IMPV. Oppenheimer Holdings Inc. restated a buy rating and issued a $60.00 price target on shares of Imperva in a research report on Tuesday, June 21st. Nomura restated a buy rating and issued a $60.00 price target on shares of Imperva in a research report on Tuesday, June 21st. BTIG Research restated a buy rating and issued a $55.00 price target on shares of Imperva in a research report on Tuesday, June 21st. Needham & Company LLC restated a hold rating on shares of Imperva in a research report on Tuesday, June 21st. Finally, Morgan Stanley restated a sell rating on shares of Imperva in a research report on Thursday, June 30th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $52.33.

Imperva (NYSE:IMPV) traded down 1.117% during trading on Tuesday, reaching $50.915. 119,124 shares of the company’s stock were exchanged. The company’s market capitalization is $1.66 billion. The company’s 50-day moving average is $48.10 and its 200-day moving average is $44.75. Imperva has a 1-year low of $31.11 and a 1-year high of $77.99.

Imperva (NYSE:IMPV) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.19. The company earned $57.87 million during the quarter, compared to analyst estimates of $66.06 million. Imperva had a negative return on equity of 25.68% and a negative net margin of 23.75%. The business’s revenue for the quarter was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.08) earnings per share. Equities research analysts expect that Imperva will post ($0.80) earnings per share for the current fiscal year.

In related news, SVP Mark E. Kraynak sold 5,582 shares of the firm’s stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $51.00, for a total transaction of $284,682.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Amichai Shulman sold 938 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $53.27, for a total transaction of $49,967.26. Following the transaction, the insider now directly owns 95,085 shares in the company, valued at $5,065,177.95. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

A number of large investors have recently made changes to their positions in the company. Fisher Asset Management LLC increased its stake in shares of Imperva by 24.1% in the third quarter. Fisher Asset Management LLC now owns 153,236 shares of the company’s stock worth $8,230,000 after buying an additional 29,807 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of Imperva by 63.6% in the third quarter. BNP Paribas Arbitrage SA now owns 3,169 shares of the company’s stock worth $170,000 after buying an additional 1,232 shares during the last quarter. Royal Bank of Canada increased its stake in shares of Imperva by 11.4% in the second quarter. Royal Bank of Canada now owns 5,457 shares of the company’s stock worth $235,000 after buying an additional 558 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Imperva by 6.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 97,461 shares of the company’s stock worth $4,192,000 after buying an additional 5,914 shares during the last quarter. Finally, Stifel Financial Corp increased its stake in shares of Imperva by 4.1% in the second quarter. Stifel Financial Corp now owns 76,685 shares of the company’s stock worth $3,298,000 after buying an additional 3,034 shares during the last quarter. Hedge funds and other institutional investors own 93.26% of the company’s stock.

Imperva Company Profile

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.

5 Day Chart for NYSE:IMPV

Receive News & Stock Ratings for Imperva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc. and related stocks with our FREE daily email newsletter.